April 23 (Bloomberg) -- Krka Group d.d., Slovenia’s biggest drug company, said an Oslo court ruled that its Swedish unit breached AstraZeneca Plc’s patent over the drug esomeprazole.
The Norwegian court ruled Krka infringed the patent because the drug contained an optical purity above 98 percent, the Novo mesto, Slovenia-based company said in a regulatory statement today. Krka said it was ordered to pay AstraZeneca about 1.9 million euros ($2.5 million) to compensate for lost profit from the reflux drug.
Krka said it will appeal the decision.
To contact the reporter on this story: Boris Cerni in Ljubljana at email@example.com
To contact the editor responsible for this story: James M. Gomez at firstname.lastname@example.org